Effectiveness of alpha-toxin Fab monoclonal antibody therapy in limiting the pathology of staphylococcus aureus keratitis

Ocular Immunology and Inflammation

Volumn 23, Issue 4, 2015, Pages 297-303

  Caballero, Armando R ^a   Foletti, Davide L ^b   Bierdeman, Michael A ^a   Tang, Aihua ^a   Arana, Angela M ^a   Hasa Moreno, Adela ^b   Sangalang, Emma Ruth B ^b   O'Callaghan, Richard J ^a  

^a UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

^b PFIZER INC   (United States)

Author keywords

Alpha toxin; erosions; Fab antibody therapy; S. aureus keratitis

Indexed keywords

ALPHA TOXIN FAB MONOCLONAL ANTIBODY; BENZALKONIUM CHLORIDE; IMMUNOGLOBULIN F(AB) FRAGMENT; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY; STAPHYLOCOCCUS ALPHA TOXIN; TOXIN ANTIBODY; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTERIAL GROWTH; BACTERIAL KERATITIS; BACTERIAL LOAD; CHEMOSIS; COLONY FORMING UNIT; CONTROLLED STUDY; CORNEA EROSION; DRUG EFFICACY; HUMAN; HUMAN CELL; IRITIS; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; SINGLE DRUG DOSE; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS AUREUS KERATITIS; STAPHYLOCOCCUS INFECTION; WESTERN BLOTTING;

EID: 84939449211     PISSN: 09273948     EISSN: 17445078     Source Type: Journal    
DOI: 10.3109/09273948.2014.920035     Document Type: Article

References (27)

1. Govindarajan B, Menon BB, Spurr-Michaud S, et al. A metalloproteinase secreted by Streptococcus pneumoniae removes membrane mucin MUC16 from the epithelial glycocalyx barrier. PLoS One. 2012; 7: e32418
2. Liesegang TJ. Bacterial keratitis. In Kaufman HE, Baron BA, McDonald MB. (eds.), The Cornea, 2nd ed. Boston: Butterworth-Heineman; 1998: 159-218
3. Wong VW, Lai TY, Chi SC, Lam DS. Pediatric ocular surface infections: a 5-year review of demographics, clinical features, risk factors, microbiological results, and treatment. Cornea. 2011; 30: 995-1002
4. Jeng BH, Gritz DC, Kumar AB, et al. Epidemiology of ulcerative keratitis in Northern California. Arch Ophthalmol. 2010; 128: 1022-1028
5. Kerr N, Stern GA. Bacterial keratitis associated with vernal keratoconjunctivitis. Cornea. 1992; 11: 355-359
6. Palmer ML, Hyndiuk RA. Contact lens-related infectious keratitis. Int Ophthalmol Clin. 1993; 33: 23-49
7. Sowka JW, Gurwood AS, Kabat AG. Handbook of Ocular Disease Management Web Site: Bacterial Keratitis. New York, NY: Jobson; 2001
8. Callegan MC, Engel LS, Hill JM, OCallaghan RJ. Corneal virulence of Staphylococcus aureus: roles of α-toxin and protein A in pathogenesis. Infect Immun. 1994; 62: 2478-2482
9. OCallaghan RJ, Callegan MC, Moreau JM, et al. Specific roles of α-toxin and β-toxin during Staphylococcus aureus corneal infection. Infect Immun. 1997; 65: 1571-1578
10. Projan S, Novick R. The molecular basis of pathogenicity. In Crossley K, Archer G. (eds.), The Staphylococci in Human Disease. New York: Churchill Livingston; 1999: 55-82
11. Chusid MJ, Davis SD. Experimental bacterial keratitis in neutropenic guinea pigs: polymorphonuclear leukocytes in corneal host defense. Infect Immun. 1979; 24: 948-952
12. Girgis DO, Sloop GD, Reed JM, OCallaghan RJ. Effects of toxin production in a murine model of Staphylococcus aureus keratitis. Invest Ophthalmol Vis Sci. 2005; 46: 2064-2070
13. OCallaghan RJ, Callegan MC, Moreau JM, et al. Specific roles of α-toxin and β-toxin during Staphylococcus aureus corneal infection. Infect Immun. 1997; 65: 1571-1578
14. Moreau JM, Sloop GD, Engel LS, et al. Histopathological studies of staphylococcal α-toxin: effects on rabbit corneas. Curr Eye Res. 1997; 16: 1221-1228
15. Dinges MM, Orwin PM, Schlievert PM. Exotoxins of Staphylococcus aureus. Clin Microb Rev. 2000; 13: 16-34
16. Bownik A, Siwicki AK. Effects of staphylococcal hemolysins on the immune system. Centrl Eur J Immunol. 2008; 33: 87-90
17. Powers ME, Kim HK, Wang Y, Bubeck WJ. ADAM10 mediates vascular injury induced by Staphylococcus aureus alpha hemolysin. J Infect Dis. 2012; 206: 352-356
18. Berube BJ, Wardenburg JB. Staphylococcus aureus α-toxin: nearly a century of intrigue. Toxins. 2013; 5: 1140-1166
19. McCormick CC, Caballero AR, Balzli CL, et al. Chemical inhibition of alpha-toxin, a key corneal virulence factor of Staphylococcus aureus. Invest Ophthalmol Vis Sci. 2009; 50: 2848-2854
20. Dajcs JJ, Austin MS, Sloop GD, et al. Corneal pathogenesis of Staphylococcus aureus strain Newman. Invest Ophthalmol Vis Sci. 2002; 43: 1109-1115
21. Dajcs JJ, Thibodeaux BA, Girgis DO, OCallaghan, RJ. Corneal virulence of Staphylococcus aureus in an experimental model of keratitis. DNA Cell Biol. 2002; 21: 375-382
22. Hume EB, Dajcs JJ, Moreau JM, OCallaghan RJ. Immunization with alpha-toxin toxoid protects the cornea against tissue damage during experimental Staphylococcus aureus k eratitis. Infect Immun. 2000; 68: 6052-6055
23. Weeks AC, Balzli CL, Caballero AR, et al. Identification and potency of cyclodextrin-lipid inhibitors of Staphylococcus aureus α-toxin. Curr Eye Res. 2012; 37: 87-93
24. Foletti D, Strop P, Shaughnessy L, et al. Mechanism of action and in vivo efficacy of a human-derived antibody against Staphylococcus aureus α-hemolysin. J Mol Biol. 2013; 425: 1641-1654
25. Hobden JA, Reidy JJ, OCallaghan RJ, et al. Treatment of experimental Pseudomonas keratitis using collagen shields containing tobramycin. Arch Ophthalmol. 1988; 106: 1605-1607
26. Wensheng C, Zhiyuan L, Jiaoyue H, et al. Corneal alternations induced by topical application of benzalkonium chloride in rabbit. PLOS One. 2011; 6: 1-8
27. Romanowski EG, Mah FS, Kowalski RP, et al. Benzalkonium chloride enhances the antibacterial efficacy of gatifloxacin in an experimental rabbit model of intrastromal keratitis. J Ocular Pharm Therapeutics. 2008; 24: 380-384